Elevated Lp(a) clinical trials at UCLA

2 in progress, 1 open to eligible people

Showing trials for

  • Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). Approximately 1700 additional participants will be enrolled in an addendum to explore Lp(a) lowering with an alternative dosing schema.

    Sylmar, California and other locations

  • Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

    Sorry, not currently recruiting here

    The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.

    Torrance, California and other locations

Our lead scientists for Elevated Lp(a) research studies include .

Last updated: